| Brand | Abnova |
| Product type | Primary antibodies |
| Reactivity | Human |
| Host species | Mouse |
| Applications | WB,IP,Flow Cyt |
| Brand: | Abnova |
| Reference: | MAB3850 |
| Product name: | ENG monoclonal antibody, clone MEM-226 |
| Product description: | Mouse monoclonal antibody raised against recombinant ENG. |
| Clone: | MEM-226 |
| Isotype: | IgG2a |
| Gene id: | 2022 |
| Gene name: | ENG |
| Gene alias: | CD105|END|FLJ41744|HHT1|ORW|ORW1 |
| Gene description: | endoglin |
| Immunogen: | Recombinant protein corresponding to human ENG. |
| Form: | Liquid |
| Recommend dilutions: | The optimal working dilution should be determined by the end user. |
| Storage buffer: | In PBS, pH 7.4 (0.09% sodium azide) |
| Storage instruction: | Store at 4°C. Do not freeze. Aliquot to avoid repeated freezing and thawing. |
| Note: | This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only. |
| Product type: | Primary antibodies |
| Host species: | Mouse |
| Antigen species / target species: | Human |
| Specificity: | This antibody reacts with CD105 (Endoglin), a 180 KDa type I homodimerizing membrane glycoprotein expressed on vascular endothelial cells (small and large vessels), activated monocytes and tissue macrophages, stromal cells of certain tissues including bone marrow, pre-B lymphocytes in fetal marrow and erythroid precursors in fetal and adult bone marrow; it is also present on syncytiotrophoblast on placenta throughout pregnancy. |
| Reactivity: | Human |
| Application image: | ![]() |
| Application image note: | Surface staining of HUVEC (human umbilical vein endothelial cells) with ENG monoclonal antibody, clone MEM-226 (Cat # MAB3850) - FITC. Total viable cells were used for analysis. |
| Applications: | WB,IP,Flow Cyt |
| Shipping condition: | Blue Ice |
| Publications: | CD105 inhibits transforming growth factor-beta-Smad3 signalling.Guo B, Slevin M, Li C, Parameshwar S, Liu D, Kumar P, Bernabeu C, Kumar S. Anticancer Res. 2004 May-Jun;24(3a):1337-45. |